In 997 adults with acute ischaemic stroke (NIHSS 7–20) treated within 48 hours in China, 10 days of IV loberamisal vs placebo raised the proportion with mRS 0–1 at 90 days (69.7% vs 56.3%; RR 1.24, 95% CI 1.12–1.36), with similar adverse event rates.
RCTn = 998
Li et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial